Welcome to our dedicated page for Aurora Cannabis news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis stock.
Aurora Cannabis Inc. reports developments in its global medical cannabis business, including product launches, brand expansion and regulated-market activity across Canada, Europe, Australia and New Zealand. The company serves medical and consumer cannabis markets through brands such as Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty's and Whistler, with GMP-certified manufacturing facilities in Canada and Germany.
Recurring announcements cover new formats such as dried flower, pre-rolls, pastilles and resin cartridges; operating and financial results; international market engagement; capital actions; and governance updates. Aurora's news also reflects its medical-first strategy and use of a global manufacturing network to supply regulated cannabis markets.
Aurora Cannabis (NASDAQ: ACB, TSX: ACB) announced that independent proxy advisory firm Institutional Shareholder Services (ISS) has recommended that shareholders vote FOR all resolutions in advance of the company’s 2026 Annual General Meeting of Shareholders.
The virtual AGM will be held on Friday, August 7, 2026, at 1:00 p.m. Eastern / 11:00 a.m. Mountain via webcast at meetnow.global/MPUKQY6. Shareholders will vote to fix the board size at five directors, elect directors, appoint the auditor, and consider a non-binding say-on-pay resolution. According to Aurora, the board unanimously recommends voting FOR all resolutions, and the voting deadline is 1:00 p.m. Eastern on Wednesday, August 5, 2026.
Safari Flower Company, a wholly owned subsidiary of Aurora Cannabis (NASDAQ/TSX: ACB), has received a three-year EU-GMP certification for its 59,000 square foot cultivation and manufacturing facility in the Niagara Region of Ontario, Canada, enhancing its ability to serve international medical cannabis markets.
Aurora acquired Safari in April 2026 to add incremental EU-GMP capacity to its global manufacturing network and support exports of high-quality medical cannabis to regulated markets, including Germany, Poland and the UK. The certification underscores Safari’s focus on quality, compliance and operational excellence.
Aurora Cannabis (NASDAQ | TSX: ACB) will host an investor conference call on Wednesday, August 5, 2026, at 8:00 a.m. Eastern | 6:00 a.m. Mountain to discuss its first quarter 2027 financial results, which will be released before market open the same day.
The call and Q&A will be led by Executive Chairman and CEO Miguel Martin and CFO Simona King. A webcast link is available via Aurora’s investor relations site under Events.
Aurora Cannabis (NASDAQ: ACB) has been named to TIME Canada's Best Companies 2026, becoming the first and only cannabis company ever recognized. The list, developed with Statista, evaluates Canadian firms with at least US$100 million revenue and positive three-year growth on employee satisfaction, revenue growth and sustainability transparency.
According to Aurora, the recognition highlights its people-first culture, leadership in Canadian medical cannabis and ongoing investment in employee development, wellness and community engagement.
Aurora Cannabis (NASDAQ:ACB) (TSX:ACB) announced that its management information circular for the 2026 annual general meeting is now available online and has been mailed to shareholders of record as of June 15, 2026.
The virtual meeting will be held on August 7, 2026, at 1:00 p.m. Eastern, and the proxy voting deadline is August 5, 2026, at 1:00 p.m. Eastern. Aurora’s board recommends shareholders vote FOR all director nominees and meeting resolutions and encourages early voting. Voting assistance is available through Kingsdale Advisors and www.MyAuroraVote.com.
Aurora Cannabis (NASDAQ:ACB) reported fiscal 2026 results, highlighting record annual global medical cannabis net revenue1 of $288.6 million, up 18% year over year, and record annual Adjusted EBITDA1 of $53.8 million, up 32%.
The company ended Q4 2026 with total net revenue1 of $84.8 million, medical cannabis net revenue1 of $77.1 million, Adjusted EBITDA1 of $9.2 million, and approximately $164.7 million in cash, short-term investments and cash equivalents2 with no debt. Aurora completed a $26.5 million acquisition of Safari Flower Company, adding a 59,000 square foot EU-GMP indoor cultivation and manufacturing facility, and divested its 50.1% stake in Bevo. For fiscal 2027, Aurora expects lower total net revenue1, adjusted gross margins1 in the mid to high 50% range, broadly stable Adjusted SG&A1, and lower annual Adjusted EBITDA1 versus fiscal 2026.
Aurora Cannabis (NASDAQ: ACB) (TSX: ACB) highlighted expanded support for Veteran communities across Canada through its Strains for Heroes program as of June 2, 2026.
Aurora donates 5% of net profits from Strains for Heroes annually to Veteran-focused organizations, up to C$200,000, backing food security, mental health, leadership and community initiatives.
Aurora Cannabis (NASDAQ: ACB) will host a fourth quarter and fiscal year 2026 investor conference call on Thursday, June 11, 2026, at 8:00 a.m. Eastern / 6:00 a.m. Mountain. Financial results will be released before market open that same day.
Executive Chairman and CEO Miguel Martin and CFO Simona King will lead the call and Q&A. A webcast link is available via Aurora’s investor relations website under Events.
Aurora Cannabis (NASDAQ: ACB) received Canadian Plant Breeders' Rights for two proprietary cannabis cultivars developed at its Aurora Coast research facility. The grant covers SOT20R07-007 (Farm Gas) and SOT20R07-005 (Driftwood Diesel), giving Aurora exclusive rights to grow, propagate and sell products from these varieties.
Both cultivars are core medical products in Germany, Poland, the UK, Canada and Australia. According to Aurora, Plant Breeders' Rights protect its proprietary genetics, support ongoing research and innovation, and, together with recent European protections, strengthen its global competitive position in medical cannabis.
Aurora (NASDAQ: ACB) is expanding its global medical cannabis portfolio with scaled product launches across Canada, Germany, Poland, Australia and other regulated markets between now and June.
New formats include dried flower, pre-rolls and pastilles, with cultivar-specific potencies (THC up to 29%) and multi-compound pastilles. Aurora cites its GMP-certified manufacturing network to support reliable international supply.